Navigation Links
Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
Date:12/20/2010

ents about Amylin, which involve risks and uncertainties.  Amylin's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amylin's most recently filed SEC documents, including its Form 10-Q.  Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... March 4, 2015 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Pedro ... The Opening Bell ® of the New York ... began trading as an NYSE MKT listed company on ... Exchange is a trusted partner to Asterias Biotherapeutics, and ...
(Date:3/4/2015)... 2015 InfuSystem Holdings, Inc. (NYSE MKT: INFU), ... services for the U.S. healthcare industry, today announced that ... financial results on Monday, March 9, 2015 after the ... a conference call for investors on Monday, March 9, ... quarter and full year 2014 performance and results.  To ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
(Date:3/4/2015)... 04, 2015 With the growing influence of ... of our teens and young adults, combined with the increasingly ... confusing to try to keep up with what kids are ... trend is replaced on a daily basis. , The same ... the slang that is used to discreetly talk about them, ...
(Date:3/4/2015)... 04, 2015 More than a year ... potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), ... it will now require manufacturers to warn patients that ... heart attacks and strokes. In a Drug Safety ... stated that it was requiring testosterone manufacturers to update ...
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... Atlanta, Georgia (PRWEB) March 04, 2015 ... Georgia, part of the School of Public Health at ... , The funds were awarded by Georgia’s Division of ... contract to support the DFCS Call Center. , ... child maltreatment by providing information and referral services that ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... adults of industrialized countries is approximately 10% and is ... is scarce. , A research article published ... Gastroenterology addresses this problem. The team lead by Dr. ... Canada, has reviewed the rate of gallstone disease and ...
... means of microsatellite markers has become an effective way ... candidate tumor suppressor genes. In a previous study, it ... frequencies, which indicated that the region might harbor the ... contained so many genes that it was inconvenient to ...
... Intraductal papillary neoplasm of the bile duct (IPN-B) is ... is a new definition of a tumor with papillary ... authors reported a case of IPN-B with interesting histopathological ... the diagnosis of bile duct dilatation due to the ...
... ARNA ) today announced it will report first ... on Wednesday, May,7, 2008. That same afternoon, Jack Lief, ... Arena,s Vice President, Finance,and Chief Financial Officer, will host ... Pacific Time) to discuss the first quarter 2008,financial results ...
... 30 The following is an,editorial from The Wall ... Committee:, [J]ohn McCain delivered another speech yesterday on ... could lead to some of the most,constructive changes to ... for his candidacy if Mr. McCain is making space ...
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
Cached Medicine News:Health News:A patient who was diagnosed as IPN-B without hepatolithiasis? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3Health News:RNC: McCain's Progress 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an...
... The FoamWalker is a cost-effective walking ... support. It has a lightweight, durable, semi-rigid ... protection. The shell's rocker sole helps reduce ... two aircells for compression and support at ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... of controlled compression and cold, the Calf ... anatomically designed cuff provides complete calf coverage ... as a single cuff, or with a ... disk). The Cooler is available separately and ...
Medicine Products: